Seeking Alpha

Cardiome enters into distribution deal for Brinavess, shares +4.9%

  • Cardiome Pharma (CRME +4.9%) says its Correvio subsidiary signed a distribution deal for its atrial fibrillation treatment Brinavess (vernakalant IV) in the Swedish market; financial details were not been disclosed.
  • Coupled with recent data that demonstrated conversion to normal sinus rhythm in ~70% of patients treated with Brinavess who were experiencing atrial fibrillation for less than 48 hours, CRME expects Sweden will be a key market for the treatment's growth.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: